Correlation Between Protagonist Therapeutics and Passage Bio

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Protagonist Therapeutics and Passage Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protagonist Therapeutics and Passage Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Protagonist Therapeutics and Passage Bio, you can compare the effects of market volatilities on Protagonist Therapeutics and Passage Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protagonist Therapeutics with a short position of Passage Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protagonist Therapeutics and Passage Bio.

Diversification Opportunities for Protagonist Therapeutics and Passage Bio

-0.16
  Correlation Coefficient

Good diversification

The 3 months correlation between Protagonist and Passage is -0.16. Overlapping area represents the amount of risk that can be diversified away by holding Protagonist Therapeutics and Passage Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Passage Bio and Protagonist Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protagonist Therapeutics are associated (or correlated) with Passage Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Passage Bio has no effect on the direction of Protagonist Therapeutics i.e., Protagonist Therapeutics and Passage Bio go up and down completely randomly.

Pair Corralation between Protagonist Therapeutics and Passage Bio

Given the investment horizon of 90 days Protagonist Therapeutics is expected to under-perform the Passage Bio. But the stock apears to be less risky and, when comparing its historical volatility, Protagonist Therapeutics is 4.14 times less risky than Passage Bio. The stock trades about -0.03 of its potential returns per unit of risk. The Passage Bio is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  70.00  in Passage Bio on September 18, 2024 and sell it today you would earn a total of  2.00  from holding Passage Bio or generate 2.86% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Protagonist Therapeutics  vs.  Passage Bio

 Performance 
       Timeline  
Protagonist Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Protagonist Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong technical and fundamental indicators, Protagonist Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.
Passage Bio 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Passage Bio are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite nearly inconsistent basic indicators, Passage Bio reported solid returns over the last few months and may actually be approaching a breakup point.

Protagonist Therapeutics and Passage Bio Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Protagonist Therapeutics and Passage Bio

The main advantage of trading using opposite Protagonist Therapeutics and Passage Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protagonist Therapeutics position performs unexpectedly, Passage Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Passage Bio will offset losses from the drop in Passage Bio's long position.
The idea behind Protagonist Therapeutics and Passage Bio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Complementary Tools

CEOs Directory
Screen CEOs from public companies around the world
Equity Valuation
Check real value of public entities based on technical and fundamental data
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities